LATANOPROSTENE Drug Patent Profile
✉ Email this page to a colleague
When do Latanoprostene patents expire, and when can generic versions of Latanoprostene launch?
Latanoprostene is a drug marketed by Gland and is included in one NDA.
The generic ingredient in LATANOPROSTENE is latanoprostene bunod. Two suppliers are listed for this compound. Additional details are available on the latanoprostene bunod profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Latanoprostene
A generic version of LATANOPROSTENE was approved as latanoprostene bunod by GLAND on April 29th, 2025.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for LATANOPROSTENE?
- What are the global sales for LATANOPROSTENE?
- What is Average Wholesale Price for LATANOPROSTENE?
Summary for LATANOPROSTENE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| DailyMed Link: | LATANOPROSTENE at DailyMed |
US Patents and Regulatory Information for LATANOPROSTENE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gland | LATANOPROSTENE BUNOD | latanoprostene bunod | SOLUTION/DROPS;OPHTHALMIC | 217387-001 | Apr 29, 2025 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
